Christopher Downs - Apr 28, 2022 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role
Chief Financial Officer
Signature
/s/ Christopher Downs
Stock symbol
CNSP
Transactions as of
Apr 28, 2022
Transactions value $
$0
Form type
4
Date filed
4/29/2022, 05:12 PM
Previous filing
Mar 14, 2022
Next filing
Feb 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNSP Restricted Stock Units Award +250K +58% 681K Apr 28, 2022 Common Stock 250K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
F2 The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
F3 Issued in connection with the reporting person's employment with the Company.